MX2010009500A - Formas de dosificacion oral solidas de valsartan y metodos para hacer estas formulaciones. - Google Patents

Formas de dosificacion oral solidas de valsartan y metodos para hacer estas formulaciones.

Info

Publication number
MX2010009500A
MX2010009500A MX2010009500A MX2010009500A MX2010009500A MX 2010009500 A MX2010009500 A MX 2010009500A MX 2010009500 A MX2010009500 A MX 2010009500A MX 2010009500 A MX2010009500 A MX 2010009500A MX 2010009500 A MX2010009500 A MX 2010009500A
Authority
MX
Mexico
Prior art keywords
formulations
making
methods
dosage forms
oral dosage
Prior art date
Application number
MX2010009500A
Other languages
English (en)
Inventor
Robert Frank Wagner
Agnes Taillardat
Amol Matharu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2010009500A publication Critical patent/MX2010009500A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se relaciona con los procesos de granulación fundida para preparar formulaciones farmacéuticas de liberación inmediata y de liberación sostenida que comprenden valsartan.
MX2010009500A 2008-02-28 2009-02-27 Formas de dosificacion oral solidas de valsartan y metodos para hacer estas formulaciones. MX2010009500A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3218708P 2008-02-28 2008-02-28
PCT/US2009/035368 WO2009108824A1 (en) 2008-02-28 2009-02-27 Valsartan solid oral dosage forms and methods of making such formulations

Publications (1)

Publication Number Publication Date
MX2010009500A true MX2010009500A (es) 2010-09-24

Family

ID=40551552

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009500A MX2010009500A (es) 2008-02-28 2009-02-27 Formas de dosificacion oral solidas de valsartan y metodos para hacer estas formulaciones.

Country Status (11)

Country Link
US (1) US20110028526A1 (es)
EP (1) EP2257288A1 (es)
JP (1) JP2011513328A (es)
KR (1) KR20100119578A (es)
CN (1) CN101951902A (es)
AU (1) AU2009219250A1 (es)
BR (1) BRPI0907151A2 (es)
CA (1) CA2713581A1 (es)
MX (1) MX2010009500A (es)
RU (1) RU2010139567A (es)
WO (1) WO2009108824A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101171375B1 (ko) 2010-01-20 2012-08-13 한올바이오파마주식회사 난용성 약물을 함유하는 경구 제형

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
AU2003225102A1 (en) * 2002-04-23 2003-11-10 Bristol-Myers Squibb Company Modified-release vasopeptidase inhibitor formulation, combinations and method
US8216609B2 (en) * 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US8268352B2 (en) * 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20040242661A1 (en) * 2003-03-17 2004-12-02 Igor Rukhman Polymorphs of valsartan
EP1868587A2 (en) * 2005-04-08 2007-12-26 Abbott Laboratories Pharmaceutical formulations comprising fenofibric acid and/or its salts
MX2007012947A (es) * 2005-04-18 2008-04-09 Rubicon Res Pvt Ltd Composiciones biomejoradas.
WO2007077581A2 (en) * 2006-01-02 2007-07-12 Rubicon Research Private Limited Pharmaceutical compositions
WO2007086078A2 (en) * 2006-01-30 2007-08-02 Panacea Biotec Ltd. Novel pharmaceutical compositions and process of preparation thereof
WO2008084504A2 (en) * 2007-01-12 2008-07-17 Rubicon Research Private Limited Pharmaceutical compositions of angiotensin ii receptor blockers
US20100278909A1 (en) * 2007-06-06 2010-11-04 Dexcel Ltd. Process for forming solid oral dosage forms of angiotensin ii receptor antagonists

Also Published As

Publication number Publication date
US20110028526A1 (en) 2011-02-03
KR20100119578A (ko) 2010-11-09
CA2713581A1 (en) 2009-09-03
WO2009108824A1 (en) 2009-09-03
JP2011513328A (ja) 2011-04-28
CN101951902A (zh) 2011-01-19
EP2257288A1 (en) 2010-12-08
BRPI0907151A2 (pt) 2015-07-07
AU2009219250A1 (en) 2009-09-03
RU2010139567A (ru) 2012-04-10

Similar Documents

Publication Publication Date Title
IL233677A (en) Benzysacazole Compounds Aminopyrazolo-Primidine Converted, Pharmaceuticals Containing Them, and Use of Drug Manufacturing Composition
MY156288A (en) Pharmaceutical formulations containing dopamine receptor ligands.
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
IL218370A0 (en) Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen, processes for producing the same and uses thereof
ZA200900345B (en) Preparation of pharmaceutical formulations
MY152279A (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
MX348823B (es) Formulaciones estables de linaclotida.
EP1895991A4 (en) MODIFIED RELEASE FORMULATIONS OF ANTI-IRRITABLE DRUGS
MX2011007267A (es) Composiciones farmaceuticas que comprenden derivados de 2-oxo-1-pirrolidina.
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
MX2011007451A (es) Composiciones farmaceuticas que comprenden derivados de 2-oxo-1 pirrolidina.
PH12015500823A1 (en) Modified release formulations for oprozomib
MY156302A (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ß-AMYLOID DISEASES AND SYNUCLEINOPATHIES
MX340188B (es) Elaboracion de granulos sin activos y tabletas que comprenden los mismos.
WO2012016683A3 (en) Oral dosage form of pregabalin
IL201465A0 (en) Self-precipitating pharmaceutical formulations for the modified release of active principle
TN2012000488A1 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
ZA200810178B (en) Pharmaceutical compositions for sustained release of phenyephrine
WO2010082220A3 (en) Sustained release pharmaceutical composition of quetiapine and process for preparation thereof
WO2010049449A3 (en) Novel salts of sunitinib
MX367327B (es) Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos.
IL213671A (en) Pharmaceutical preparations containing alglitazar, a process for their preparation and use for the preparation of medicines
EA201200485A1 (ru) Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол
WO2010006904A3 (en) Crystalline forms of rabeprazole sodium
MX2012002631A (es) Capsulas con aroma.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal